Standard Temodal (Temozolomide) Regimen Versus Standard Regimen Plus Early Postsurgery Temodal for Newly Diagnosed Glioblastoma Multiforme (Study P05572)

Inclusion Criteria: Only the patients who meet all these criteria can be enrolled in the study: * Patients with prior histological confirmation of newly diagnosed primary glioblastoma multiforme in supratentorial cerebral hemisphere. * Gross total resection or partial resection (imaging) \>70%. * At least be capable to obtain a tissue sample for MGMT analysis during surgery. * Chemo-radiotherapy to be expected from Week 5 (Day 29) after surgery. * Age \>=18 and \<=70 years. * Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2. * Life expectancy \>=9 months. * Laboratory test values must satisfy the following criteria: * absolute neutrophil count \>=1.5 x 10\^9/L; * platelet count \>=100 x 10\^9/L; * hemoglobin \>=80 g/L; * blood urea nitrogen and creatinine \< 1.5 x upper limit of normal value (ULN); * total bilirubin and direct bilirubin \< 1.5 x ULN; * alanine aminotransferase and aspartate aminotransferase \< 3 x ULN; * alkaline phosphatase \< 2 x ULN. * Patients must be willing to provide written informed consent. * Patients of child-bearing potential (including female subjects and the female partners of male subjects) must use an effective method of contraception. Exclusion Criteria: Patients will not be enrolled if any of the following criteria apply: * Patient with previous or current malignancies (except melanoma) at other sites, unless disease free for at least 3 years. * Patient who received chemotherapy, radiotherapy for study indication, or other medications for antitumor indication prior to surgery. * Patient with recurrent or multiple malignant glioma (including gliomatosis cerebri). * Patient with metastatic lesions at the subtentorial or outside of calvaria. * Patient who received chemotherapy or radiotherapy sensitizers for head or neck tumor. * Patient who received radiotherapy at head or neck which leads to radiotherapy domain overlapping. * Patient with acute infections requiring intravenous antibiotics. * Frequent vomiting or medical condition that could interfere with oral medication intake (eg, partial bowel obstruction). * Known human immunodeficiency virus (HIV)-positive or acquired immune deficiency syndrome (AIDS)-related illness. * Woman who is pregnant or breastfeeding. * Patient with a history of hypersensitivity to temozolomide or other analogic alkylating agents. * Patient with any other conditions under which investigators think the subject is not suitable for enrolment, such like having known that the subject may not have good compliance.